If you have been managing back pain for months or years without enough relief, you may be wondering whether there is another legal option. The short answer is yes. You can get medical cannabis for back pain in the UK through a private specialist clinic, provided you meet certain clinical criteria. This article explains what those criteria are, what the evidence shows, and how the process works.
Key Takeaways
- Medical cannabis is legally available in the UK for chronic back pain through private specialist clinics, with no GP referral needed
- To qualify, you generally need a confirmed diagnosis and evidence that at least two prior treatments have not provided adequate relief
- A 2025 Phase 3 trial published in Nature Medicine found cannabis-based treatment significantly reduced pain intensity in 820 adults with chronic lower back pain
- Medical cannabis has been prescribed fewer than five times on the NHS since it became legal in 2018; private medical cannabis clinics are the realistic route for most back pain patients
- A free eligibility check is the first step with no commitment required
What Type of Back Pain Can Be Considered for a Cannabis Prescription?
For a specialist to consider a cannabis-based prescription, the pain generally needs to have been present for 12 weeks or more, separating chronic back pain from a short-term injury that resolves on its own.
Two main types matter for eligibility:
- Nociceptive pain comes from damage to muscles, discs, or joints.
- Neuropathic pain comes from nerve irritation or damage, such as sciatica, often producing burning or shooting sensations.
Many people experience a mix. The neuropathic element generally has the stronger evidence base for cannabis-based medicines, though a specialist assesses this individually. Our chronic back pain resource covers the full clinical picture.
Chronic pain was the primary condition for 53.5% of patients enrolled in the Project Twenty21 (T21) registry, making back pain the most common reason people seek a private cannabis prescription.⁴
Does Medical Cannabis Help with Back Pain? What the Research Shows
The most significant development in the evidence for medical cannabis for chronic back pain UK came in 2025.
The 2025 Phase 3 Trial: The Strongest Evidence Yet
A Phase 3 randomised placebo-controlled trial by Karst et al. in Nature Medicine (September 2025) enrolled 820 adults with chronic lower back pain (CLBP) and is the highest-quality study yet for this condition. ¹ Pain was measured using the numeric rating scale (NRS).
- Patients receiving the full-spectrum cannabis extract saw mean pain reduction of 1.9 NRS points versus 1.3 in placebo, a statistically significant difference. ¹
- Sleep quality improved by 2.2 NRS points in the treatment arm versus 1.5 in placebo. In the open-label extension, pain reduction continued to 2.9 NRS points at six months.
Adverse events were more common in the cannabis group (83.3% versus 67.3%), but were predominantly mild to moderate and occurred in the initial titration phase. No signs of dependence or withdrawal were observed. The withdrawal endpoint was not statistically significant.
UK Real-World Data
UK registry data supports these findings. The T21 registry, run by Drug Science, enrolled over 4,000 patients. At three months, chronic pain patients showed significant improvements in pain intensity, pain interference, quality of life, mood, and sleep. ²
Among 350 opioid-using patients, daily opioid use fell from 45mg to 19mg morphine milligram equivalent (MME), an observational finding consistent with an opioid-sparing effect. The UK Medical Cannabis Registry (UKMCR) found statistically significant improvements in Brief Pain Inventory (BPI) scores in chronic pain patients at one, three, and six months. ³
The National Institute for Health and Care Excellence (NICE) does not currently recommend cannabis-based products for medicinal use (CBPMs) for chronic pain. ⁵ This guidance predates the 2025 Phase 3 trial. Private specialist clinicians assess each patient individually, outside the NICE pathway.
Can You Get Medical Cannabis for Back Pain in the UK? Eligibility Explained
Assessing eligibility for a back pain medical cannabis prescription UK involves three things: a confirmed diagnosis of a chronic back pain condition, evidence that at least two prior treatments have not provided adequate relief or were stopped due to side effects, and no relevant contraindications.
For back pain, prior treatments typically include non-steroidal anti-inflammatory drugs (NSAIDs), physiotherapy, weak opioids, nerve pain medications such as gabapentin or pregabalin, or steroid injections. Non-pharmaceutical treatments count too.
Are you Eligible for Medical Cannabis?
Consider someone managing lower back pain for three years who completed physiotherapy that helped but did not resolve the pain, then found NSAIDs caused stomach problems they could not tolerate long-term. Sleep is now affected, and a shooting pain down one leg suggests a neuropathic element. That kind of history, with two prior treatments and documented functional impact, is typically what a specialist wants to review.
How to Get a Medical Cannabis Prescription for Back Pain
Start with the free online eligibility check, which takes a few minutes at no cost. If eligible, book an initial video consultation with a GMC-registered specialist clinician (check for pricing details), refundable if treatment is not appropriate. No GP referral is required. The specialist reviews your diagnosis, treatment history, current symptoms, and contraindications before making a prescribing decision.
What happens after the initial video consultation?
If a CBPM is appropriate, the prescription goes to a licensed pharmacy partner and medication is delivered within 48 hours in plain, discreet packaging with no indication of the contents on the outside.
Follow-up consultations every 60 to 90 days allow the clinician to review progress and adjust the formulation if needed. If grogginess or side effects occur, the formulation is reviewed. CBD-dominant and lower-THC options are generally associated with less next-day sedation. See how the full process works at LeafEase for a full walkthrough.
How LeafEase Supports Back Pain Patients with Prescribed Medical Cannabis
LeafEase is registered with the Care Quality Commission (CQC), and all prescriptions are issued by GMC-registered specialist clinicians. Consultations take place by video, accessible from anywhere in the UK with no travel required. Medication starts from approximately £50 per month at the lower end. The LeafEase Advantage subscription package includes follow-up consultations with the same clinician who knows your history, formulation reviews built around your daily routine, and free home delivery, making it an ongoing clinical relationship rather than a one-off transaction.
Your Next Step with LeafEase
If you have been managing back pain for a long time and feel you have reached the limits of what standard treatments can offer, checking your eligibility takes a few minutes and gives you a clearer picture of whether a specialist consultation is worth pursuing.
Frequently Asked Questions
Can you get medical cannabis for back pain in the UK?
Yes. Medical cannabis can be prescribed for chronic back pain in the UK through a private specialist clinic, provided you meet the eligibility criteria. These include a confirmed diagnosis and evidence that at least two prior treatments have not given you adequate relief. A GMC-registered specialist makes the final assessment during a consultation, and no GP referral is needed.
Does medical cannabis help with back pain?
Research suggests it may, particularly for chronic lower back pain with a neuropathic element. A Phase 3 trial published in Nature Medicine in September 2025 found that a full-spectrum cannabis extract reduced pain intensity significantly more than placebo in 820 adults with chronic lower back pain, with improvements sustained over several months. UK real-world data from Project Twenty21 showed meaningful improvements in pain intensity and pain interference in chronic pain patients at three months. Individual responses vary and a specialist assesses suitability on a case-by-case basis.
Is medical cannabis available on the NHS for back pain?
Medical cannabis has been prescribed fewer than five times on the NHS since it became legal in 2018.⁷ For chronic back pain specifically, NICE does not currently recommend cannabis-based medicines, meaning NHS access is not a realistic route for most patients. Private specialist clinics assess patients individually and can prescribe outside the NICE pathway where clinically appropriate.
What treatments do I need to have tried before getting a cannabis prescription for back pain?
Typically, you need to have tried at least two treatments without adequate relief. For back pain, these commonly include NSAIDs, physiotherapy or manual therapy, weak opioids, nerve pain medications, or steroid injections. They do not all have to be prescription medications. Treatments tried and found insufficient or discontinued due to side effects all count. A specialist will review your treatment history in detail during the consultation.
Will medical cannabis make it unsafe to drive?
Medical cannabis can impair your ability to drive or operate machinery. You must not drive if you feel drowsy, dizzy, or otherwise affected, regardless of whether your prescription is legal. Your specialist will advise on timing and how to manage treatment around activities requiring full concentration. If side effects affect your ability to drive, the clinician will review and adjust your formulation.
How long does it take to get a medical cannabis prescription for back pain?
From eligibility check to first delivery, the process is usually completed within one to two weeks. Once a prescription is issued, medication is dispatched by the licensed pharmacy partner within 48 hours. The exact timeline depends on consultation availability and individual assessment.
What does medical cannabis for back pain cost per month?
Medication starts from approximately £50 per month at the lower end for patients on lower-dose formulations, rising depending on product type and dose. Follow-up consultations at LeafEase are £75 on a pay-as-you-go basis, or included in the LeafEase Advantage subscription at £31.99 per month, which also covers free home delivery. The initial consultation is £85. A specialist will outline expected costs during your first appointment.
References
[1] Karst, M., Meissner, W., Sator, S., Keßler, J., Schoder, V. & Häuser, W. (2025) Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. Nature Medicine, 31, pp.4189-4196. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12705446/ [Accessed: July 2026].
[2] Lynskey, M.T., Schlag, A.K., Athanasiou-Fragkouli, A., Badcock, D. & Nutt, D.J. (2023) Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: Real-world evidence from Project Twenty21. Drug Science, Policy and Law, 9, 20503245231167373. Available at: https://journals.sagepub.com/doi/full/10.1177/20503245231167373 [Accessed: July 2026].
[3] Lintzeris, N. et al. (2021) Clinical outcome data of first cohort of chronic pain patients treated with cannabis-based sublingual oils in the United Kingdom: analysis from the UK Medical Cannabis Registry. PubMed Central. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9292210/ [Accessed: July 2026].
[4] Schlag, A.K. et al. (2022) Characteristics of people seeking prescribed cannabinoids for the treatment of chronic pain: Evidence From Project Twenty21. Frontiers in Pain Research. Available at: https://pubmed.ncbi.nlm.nih.gov/35775024/ [Accessed: July 2026].
[5] National Institute for Health and Care Excellence (2021) Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. NICE Guideline NG193. Available at: https://www.nice.org.uk/guidance/ng193 [Accessed: July 2026].
[6] National Institute for Health and Care Excellence (2020) Low back pain and sciatica in over 16s: assessment and management. NICE Guideline NG59. Available at: https://www.nice.org.uk/guidance/ng59 [Accessed: July 2026].
[7] The Pharmaceutical Journal (2023) Demystifying medical cannabis: five years on from legalisation. Available at: https://pharmaceutical-journal.com/article/feature/demystifying-medical-cannabis-five-years-on-from-legalisation [Accessed: July 2026].
[8] Medicines and Healthcare products Regulatory Agency (MHRA) (2019) Cannabis-based products for medicinal use (CBPMs). Available at: https://www.gov.uk/guidance/cannabis-based-products-for-medicinal-use-cbpms [Accessed: July 2026].
